HIGHLIGHTS
- who: . Significance and collaborators from the Department of Medical Oncology, Division of Cancer Medicine, the University of Texas MD have published the Article: A Phase II Study of Glembatumumab Vedotin for, in the Journal: (JOURNAL)
- what: Given these promising preclinical results and the biological plausibility of the anti-tumor mechanism, this phase II study was undertaken to determine the effect of single-agent GV on 3 of 12 the overall response of patients with metastatic uveal melanoma while also determining the clinical safety, pharmacodynamics, and GPNMB expression of tumors.
SUMMARY
In . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.